Middle East & Africa Eyelid Surgery Blepharoplasty Market Growth Prospects 2024-2032

Middle East & Africa Eyelid Surgery Blepharoplasty Market Growth Prospects 2024-2032

Triton’s analysis estimated that the Middle East and Africa eyelid surgery blepharoplasty market is set to garner revenue at 7.16% CAGR over the forecast years 2024-2032.

The eyelid surgery blepharoplasty market in the Middle East and South Africa is expanding, driven by a growing emphasis on aesthetics and rising awareness of advanced cosmetic procedures. In the Middle East, cultural preferences for well-defined facial aesthetics contribute significantly to the demand, with Dubai emerging as a key hub for cosmetic surgery due to its skilled surgeons and modern facilities. Similarly, with 5864 eyelid surgeries in South Africa, blepharoplasty is gaining popularity among both men and women. Thus, the accessibility of advanced techniques, such as laser-assisted and scarless blepharoplasty, further fuels market growth in this region.

The countries examined in this region include the United Arab Emirates, Saudi Arabia, Israel, South Africa, and Rest of Middle East & Africa.

In 2023, the United Arab Emirates leads with the highest revenue share for the eyelid surgery blepharoplasty market.

• The UAE’s beauty-conscious population and booming medical tourism drive the popularity of blepharoplasty. For instance, the average cost of blepharoplasty in Dubai approximately ranges between $3,040 and $4,140, which is competitive given the region’s world-class healthcare facilities. This pricing attracts both local and international patients seeking high-quality results at reasonable costs.
• Eyelid surgery in Dubai has a success rate of over 95% in achieving desired cosmetic results, as noted in a study published in the Journal of Plastic, Reconstructive & Cosmetic Surgery. Serious complications are exceedingly rare, with less than 1% of patients experiencing significant difficulties.
• Dubai surgeons use cutting-edge technologies and global expertise for precise and premium results, which has led to the expansion of the eyelid surgery blepharoplasty market in the UAE.

Eyelid Surgery Blepharoplasty Market Trends in Saudi Arabia

The Ministry of Health’s report indicating that 13% of the 170,000 non-critical surgeries conducted in Saudi Arabia during the first half of 2023 were eyelid surgeries highlights a significant demand for blepharoplasty procedures in the country. This suggests that a considerable number of individuals are seeking cosmetic enhancements to address issues such as drooping eyelids, puffiness, and wrinkles around the eyes. The high volume of these procedures reflects a growing trend towards aesthetic surgery in Saudi Arabia, possibly driven by increasing awareness and acceptance of cosmetic procedures. This trend is likely to widen the scope of the reviewed market in the coming years.

The market segments for eyelid surgery blepharoplasty consist of product type, end-user, procedure type, and gender. The product type segment includes laser shield, laser instrument, and surgical instrument. Laser shield is an advanced technology that includes devices that utilize laser energy to precisely target tissues, providing benefits such as reduced bleeding, faster healing, and minimized scarring. Laser shields are increasingly favored in blepharoplasty procedures as they offer more controlled and less invasive techniques compared to traditional methods, making them appealing to both patients and surgeons.

Contender Analysis in the Eyelid Surgery Blepharoplasty Market:

Sisram Medical Ltd creates energy-based aesthetic platforms that integrate laser, light, and radiofrequency technologies for minimally invasive facial and delicate eye area rejuvenation. Their latest innovation, the Allegro Multi-platform, enables simultaneous fractional CO2 skin revitalization and plasma blepharoplasty procedures, offering complete facial renewal without surgery. The company is headquartered in Caesarea, Israel.

In October, the company announced NMPA approval for DAXXIFY®, the world’s first and only peptide-powered botulinum toxin product, now available in Mainland China.

Some other notable contenders in the eyelid surgery blepharoplasty market are LightScalpel, London Bridge Plastic Surgery, Osheru LLC, IOPtima, and Sciton Inc.